NeuroSense Therapeutics Ltd. (NRSN) - Company Total Revenue
NeuroSense Therapeutics (NRSN) develops therapies for ALS and Alzheimer's disease while strictly adhering to biohazardous waste disposal standards. The company's commercial sales volume visualizes actual cash flow without speculation, with the indicator reaching 0.00. High business scalability is driven by patents that enable the global distribution of innovative drugs with minimal production costs.
Analytical breakdowns for NeuroSense Therapeutics Ltd (NRSN)
- market value and analyst target forecast:
- market capitalization indicators:
- book value of equity indicators:
- company liabilities and liquidity data:
Debt to Capital NeuroSense Therapeutics|NRSN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital NeuroSense Therapeutics, Ltd.|NRSN - Company Total Debt|Debt to Book Capital NeuroSense Therapeutics Ltd.|NRSN - Company Long-Term Debts|Company Short-Term Loans and Borrowings NeuroSense Therapeutics|Immediate Liquidity neurosense-tx.com
- financial results and valuation multiples details:
NRSN - Company Net Income|Expected Net Income NeuroSense Therapeutics|NRSN - P/E Multiple|Forward P/E Multiple NeuroSense Therapeutics, Ltd.|NRSN - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio NeuroSense Therapeutics Ltd.|NRSN - Operating profit EBITDA|Net earnings per one share for the last twelve months NeuroSense Therapeutics|NRSN - Net earnings per share for the last 12 months|Quarterly EPS earnings growth neurosense-tx.com|NRSN - Net earnings per share growth this year|Projected earnings per share increase next year NeuroSense Therapeutics
- sales volume and revenue indicators:
General company analysis:neurosense-tx.com, NRSN
NeuroSense Therapeutics (NRSN) maintains a strong position in the neurodegenerative pathology sector thanks to a diversified patent portfolio. By analyzing the company's gross sales revenue, an investor can see the actual daily cash inflow from clients. This metric captures real liquidity and allows for the prompt detection of cash gaps or deviations from the financial plan. Stable growth in this indicator confirms the commercial viability of current clinical trial programs.
Key competitors
Biogen Idec (BIIB) - Company Gross Revenue|Revenue and Sales Volume NBIX|RGC - Company Total Revenue|Company Revenue Axsome Therapeutics, Inc. AXSM|ACAD: Company Sales Volume|XENE - Company Revenue|Company Gross Revenue Viking Therapeutics Corp VKTX|SUPN: Revenue and Sales Volume|Company Total Revenue catalystpharma.com (CPRX)|Company Sales DNLI|HRMY: Company Sales Revenue|Company Sales BHVN (Biohaven Pharmaceutical)|Company Total Sales AMLX|Revenue and Sales Volume TRVI (Trevi Therapeutics)|Company Sales Revenue PRAX|Anavex Life Sciences Corp. - Revenue and Sales Volume|Company Total Revenue CeriBell Inc|Prothena Corporation PLC (PRTA) - Company Revenue|Alector - Company Sales Revenue|ANNX (Annexon, Inc.) - Revenue and Sales Volume|Revenue and Sales Volume Omeros Corp.|Company Revenue Neurogene (NGNE)|ACIU: Company Annual Revenue|Revenue and Sales Volume VYGR (Voyager Pharma)|Neumora Corp (NMRA) - Company Total Revenue|SCLX: Company Sales|TVGN - Revenue and Sales Volume|ACOG (alphacognition.com) - Company Sales|CGTX: Company Total Sales|IKT (Inhibikase) - Revenue and Sales Volume|Cassava Pharma (SAVA) - Company Gross Revenue|Revenue and Sales Volume ASRT|Company Sales coyatherapeutics.com COYA|Company Revenue Vistagen VTGN|Company Gross Revenue Ovid Therapeutics Inc (OVID)|ABOS - Company Revenue|CRVO (CervoMed Corporation) - Company Sales Volume|alteritytherapeutics.com (ATHE) - Company Revenue|Clene - Company Sales Revenue|Company Revenue PepGen Inc|jupiterneurosciences.com (JUNS) - Company Gross Revenue|Company Revenue Relmada (RLMD)|Annovis Bio Corporation - Company Sales Volume|Company Revenue Grace Therapeutics GRCE|AIFF: Company Sales Volume|ANEW Medical, Inc. - Revenue and Sales Volume|Company Total Revenue Reviva Pharmaceuticals Holdings Inc.|MTVA (metaviatx.com) - Company Sales|NeurAxis Inc (NRXS) - Revenue and Sales Volume|Company Revenue Helius Medical Technologies, Inc.|PASG: Company Sales Revenue|Company Revenue Neuphoria Therapeutics Inc. (NEUP)|NERV - Company Total Revenue|Company Revenue Athira ATHA|ADXN: Company Sales Volume|Alzamend - Revenue and Sales Volume|Company Total Revenue Cyclerion Therapeutics|PTIX (protagenic.com) - Company Sales|Pasithea Therapeutics Corp. (KTTA) - Revenue and Sales Volume|Company Revenue Cortigent Inc|ATXI: Company Sales Revenue|Company Revenue Brainstorm Cell (BCLI)|CARA - Company Total Revenue|Company Revenue Chromocell Therapeutics Corp. CHRO|Company Gross Revenue Eliem Therapeutics, Inc. (ELYM)|Intra-Cellular - Revenue and Sales Volume|Company Total Revenue Longboard|Marinus Pharmaceuticals (MRNS) - Company Revenue|Company Sales Volume NKGN|Company Revenue NeuroBo Pharmaceuticals, Inc.|Sage Therapeutics Inc. (SAGE) - Company Gross Revenue|Revenue and Sales Volume SNPX|TRVN - Company Total Revenue|Vigil Neuroscience, Inc. - Company Sales|Company Sales Revenue WENA|CERE: Company Sales
